Claudia Omarini
Parma, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 49 publications
Time to next treatment to evaluate the therapeutic sequence after first- or second-line CDK4/6 inhibitors of hormone receptor-positive, HER2-negative advanced breast cancer in Italy: a retrospective/prospective observational trial GOIRC-04-2019.
Journal: ESMO real world data and digital oncology
Published: February 06, 2026
Circulating tumor DNA and Response Evaluation Criteria In Solid Tumors: ctDNA-RECIST proof-of-concept in HER2-positive metastatic breast cancer.
Journal: Journal of experimental & clinical cancer research : CR
Published: July 11, 2025
The administration of proton pump inhibitors with the CDK4/6 inhibitor abemaciclib does not affect the clinical outcome of metastatic breast cancer patients.
Journal: Therapeutic advances in drug safety
Published: June 24, 2025
Update on Pulmonary Toxicity Induced by New Breast Cancer Treatments.
Journal: Breast cancer (Dove Medical Press)
Published: August 23, 2024
Safety and efficacy analysis of neoadjuvant pertuzumab, trastuzumab and standard chemotherapy for HER2-positive early breast cancer: real-world data from NeoPowER study.
Journal: BMC cancer
Published: March 03, 2024
Monitoring changing patterns in HER2 addiction by liquid biopsy in advanced breast cancer patients.
Journal: Journal of experimental & clinical cancer research : CR
Published: February 12, 2024
Real-World Data and Clinical Implications of Next-Generation Sequencing (NGS)-Based Analysis in Metastatic Breast Cancer Patients.
Journal: International journal of molecular sciences
Published: January 16, 2024
Adjuvant Endocrine Therapy in Premenopausal Women With Hormone Receptor-Positive Early-Stage Breast Cancer: Risk Stratification in a Real-World Setting.
Journal: Clinical breast cancer
Published: April 26, 2023
Thromboembolism and Adjuvant Endocrine Therapy (AET) in Hormone Receptor-Positive Early Breast Cancer (EBC): Did Treatment Evolution Change Incidence of the Adverse Event? A Meta-Analysis.
Journal: Clinical breast cancer
Published: December 13, 2022
Targeting PI3K/AKT/mTOR Pathway in Breast Cancer: From Biology to Clinical Challenges.
Journal: Biomedicines
Published: November 27, 2022
Concomitant administration of proton pump inhibitors does not significantly affect clinical outcomes in metastatic breast cancer patients treated with ribociclib.
Journal: Breast (Edinburgh, Scotland)
Published: August 10, 2022
Last Updated: 09/26/2026